Endeavor BioMedicines Secures Orphan Drug Designation for Taladegib in Both U.S. and Europe for Idiopathic Pulmonary Fibrosis
Thursday, July 17, 2025
Endeavor BioMedicines has received Orphan Drug Designation for its investigational treatment, taladegib (ENV-101), from both the U.S. Food and Drug Administration (FDA) and the European Commission (EC).
Taladegib is a Hedgehog signalling pathway inhibitor that targets a specific receptor to prevent abnormal myofibroblast accumulation a key contributor to fibrosis. By addressing this mechanism, the therapy aims to interrupt the disease process and improve lung health.
IPF affects more than 150,000 adults in the United States. The condition results from repeated damage to lung tissue, leading to persistent scarring and impaired respiratory function. With few treatment options currently available, IPF is associated with a poor prognosis, with an average survival of three to five years following diagnosis.
The designation supports the potential use of taladegib in treating idiopathic pulmonary fibrosis (IPF), a serious and progressive lung disease with limited treatment options.
In the United States, Orphan Drug Designation is awarded to therapies targeting diseases that affect fewer than 200,000 individuals. Benefits include development support, financial incentives, and a potential seven-year market exclusivity period upon approval.
Orphan Drug Designation is granted in the European Union to encourage the development of treatments for rare and life-threatening conditions affecting no more than five in 10,000 people.
The company is currently enrolling patients in a global Phase 2b clinical trial, WHISTLE-PF (Wound-remodelling Hedgehog-Inhibitor ILD Study Testing Lung Function Endpoints-PF), which is evaluating the safety, efficacy, and tolerability of taladegib in individuals with IPF. The study is expected to complete enrolment by 2026.
The designation offers regulatory incentives, including eligibility for protocol assistance, fee reductions, and up to ten years of market exclusivity following approval.
Source: endeavorbiomedicines.com
